RADeep funding

Sources of funding

RADeep is promoted by the EuroBloodNet Association constituted on February 1st, 2018 in Paris (n° W751243310) located at the service d'hématologie séniors,- Trèfle 4 (head, Prof Pierre FENAUX) at hôpital Saint Louis - 1 Avenue Claude Vellefaux - 75010 Paris, France.

RADeep is led by a consortium formed by Dr. María del Mar Mañú Pereira (Hospital Universitari Vall d'Hebrón - Vall d'Hebrón Institut de Recerca, Barcelona, Spain), Prof. Beatrice Gulbis (Hôpital ERASME, Brussels, Belgium), and Dr. Marina Kleanthous (Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus).

Hospital Universitari Vall d'Hebrón - Vall d'Hebrón Institut de Recerca is the RADeep's controller to regards of General Data Protection Regulation.

RADeep is co-financed by public funds and through EuroBloodNet Association by private funds from pharmaceutical companies to facilitate the gathering of data and processing of data for disease-specific outcomes. However, pharmaceutical companies will not be granted with access to any personal data that allows patients’ identification. Data shared with pharmaceutical companies will follow the same established policies for the transfer of data to other third parties, as researchers or patients associations.

The following private sources are contributing to RADeep data gathering and processing:

  • Novartis AG, January 2020 - December 2022, mainly contribution to SCDeep (Sickle Cell Disease disease specific arm)
  • Agios Pharmaceuticals Inc, July 2017 – December 2020, mainly contribution to PKDeep (Pyruvate Kinase Deficiency disease specific arm)

Euro Blood Net